Navigation Links
Growing Focus on Reducing Drug Development Costs to Drive the Market for Biosimulation, According to a New Trend Report Published by Global Industry Analysts, Inc.
Date:1/7/2014

San Jose, California (PRWEB) January 07, 2014

Follow us on LinkedIn – Growing instances of drug failures in late stage clinical trials is throwing the spotlight on biosimulation. Defined as the use of computers to simulate biological processes, biosimulation is growing in popularity with pharmaceutical companies stepping up investments in this space. Key factors driving adoption of biosimulation tools and solutions among drug developers include growing regulatory, competitive, and budgetary pressures. Broader adoption of pharmacokinetic, and pharmacodynamic modelling in pre-clinical drug discovery is also expected to drive growth in the market.

The trend report titled “Biosimulation” announced by Global Industry Analysts Inc., is a focused research paper which provides cursory insights into the technology, its evolution, applications, future prospects, and corporate initiatives of key companies worldwide. The report provides global market estimates and projections for Biosimulation in US dollars for the years 2012 through 2017. The report also offers coverage on key companies such as Accelrys Inc., Advanced Chemistry Development Inc., Chemical Computing Group Inc., Entelos Inc., GNS Healthcare, In Silico Biosciences Inc., Insilico Biotechnology AG, Molecular Knowledge Systems Inc., Novo Nordisk A/S, Rhenovia Pharma SAS, Simulations Plus Inc., Synergix Ltd., and TheraSim, among others.

For more details about this trend report, please visit http://www.strategyr.com/TrendReport.asp?code=146055.

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

Read the full story at http://www.prweb.com/releases/biosimulation_market/drug_development/prweb11467659.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Growing Research Focus on Single Cell Biology Drives the Market for Single Cell Omics, According to a New Trend Report Published by Global Industry Analysts, Inc.
2. Intrexon Strengthens Leadership in Companys Rapidly Growing Health Sector
3. Embry-Riddle to Launch Forensic Biology Degree to Meet Growing Need for DNA Experts
4. Growing Interest in Regenerative Medicine to Drive the Mesenchymal Stem Cells Market, According to a Soon to Be Released Report by Global Industry Analysts, Inc.
5. Inc. Magazine Unveils Its Annual Exclusive List of America’s Fastest-Growing Private Companies—the Inc.500
6. 5000
7. Envera Files Patent for Low Temperature Growing Bacteria
8. Russias Top 50 Fast-Growing High-Tech Companies
9. New Enterprise Associates Opens Boston Office To Serve Growing Portfolio, Pursue New Investments
10. Workforce Solutions Company Kaztronix is Recognized for the Second Time on Inc. Magazine's List of the 5000 Fastest-Growing Private Companies in America
11. Indigo BioSystems, Inc. Ranks in the 2013 Inc. 500
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... Ginkgo Bioworks, the organism company, announced ... the synthesis and assembly of DNA. The acquisition ... synthetic DNA into Ginkgo,s automated organism engineering foundries, ... of new organism designs for application across a ... founded to significantly increase the world,s capacity to ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):